Expanded partnerships IRBM has a track record of collaborations with major industry players (MSD, AstraZeneca, Merck) and global institutions, indicating strong partnership potential for CRO services and co-development opportunities.

Integrated capabilities A single, unified research facility with in-house oncology and other assets positions IRBM to offer end-to-end drug discovery support, appealing to sponsors seeking streamlined, integrated outsourcing and faster time-to-candidate.

Global exposure Active participation in high-profile events (G7 ministerial meeting, AACR, BIO-Europe) and recent Boston office expansion signal ongoing international market engagement and potential for cross-border collaboration and new client acquisition.

Tech enablement Adoption of diverse tech stack (CRM, marketing automation, analytics, SES tools) suggests capacity to scale client engagement, track project workflows, and deliver data-driven CRO services with enhanced transparency.

Finite scale opportunity Revenue and employee figures place IRBM as a mid-sized CRO with growth potential in oncology and therapeutics, offering clear upsell opportunities for additional services, internal pipeline collaboration, and expansion of sponsored research programs.